- ￥1
- Cayman
- 16043-1 mg
- 2025年07月16日
14 年钻石会员
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
一种口服活性的Xa因子直接抑制剂(Ki=0.4nM)，可抑制凝血酶形成而不延长出血时间；已获准在临床上用作预防中风和治疗静脉血栓栓塞的抗凝剂。An orally active, direct inhibitor of Factor Xa (Ki = 0.4 nM) that inhibits thrombin formation without prolonging bleeding time; approved for clinical use as an anticoagulant in the prevention of stroke and the treatment of venous thromboembolisms.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验相关实验
Oral Direct Factor Xa Inhibitors, with Special Emphasis on Rivaroxaban
Rivaroxaban is a small-molecule, direct factor Xa inhibitor that is under investigation for the prevention and treatment of venous and arterial thrombosis. To date, oral anticoagulants have been limited largely to vitamin K antagonists
Novel Anticoagulant Therapy: Principle and Practice
(dabigatran), oral-direct factor Xa inhibitors (rivaroxaban, apixaban, YM-150, DU-176b), and tissue factor/factor VIIa complex inhibitors have been “tailor-made” to target specific procoagulant complexes and have the potential to greatly expand oral
技术资料暂无技术资料 索取技术资料
Rivaroxaban
￥1
